A recent study provides more evidence that patients with psoriasis–even mild cases–face a higher risk of major depression, a finding that could lead dermatologists to alert patients with the condition and even screen them for mental health issues.
Cumulative dosing of isotretinoin has followed a reference range of 120 to 150 mg/kg, but there is an absence of strong evidence supporting this recommendation, pointing to the need for clinicians to treat their patients to achieve clearance of acne rather than adhere to this range.
Neuroinflammation has recently been recognized as one of the possible factors leading to the development of rosacea. As such, future therapies targeting this pathway could prove effective in rosacea treatment.
Researchers presented new data on the use of the fully human IL-17A inhibitor Cosentyx (secukinumab, Novartis) in moderate-to-severe psoriasis, at the 25th European Academy of Dermatology and Venereology (EADV) Congress in Vienna, Austria, September 28 through October 2, 2016.